Synthetic platelet microgels containing fibrin knob B mimetic motifs enhance clotting responses.
biomimetic
clotting
fibrin
hemorrhage
knob B
synthetic platelets
trauma
wound healing
Journal
Advanced therapeutics
ISSN: 2366-3987
Titre abrégé: Adv Ther (Weinh)
Pays: Germany
ID NLM: 101724632
Informations de publication
Date de publication:
10 May 2021
10 May 2021
Historique:
entrez:
7
6
2021
pubmed:
8
6
2021
medline:
8
6
2021
Statut:
ppublish
Résumé
Native platelets are crucial players in wound healing. Key to their role is the ability of their surface receptor GPIIb/IIIa to bind fibrin at injury sites, thereby promoting clotting. When platelet activity is impaired as a result of traumatic injury or certain diseases, uncontrolled bleeding can result. To aid clotting and tissue repair in cases of poor platelet activity, our lab has previously developed synthetic platelet-like particles capable of promoting clotting and improving wound healing responses. These are constructed by functionalizing highly deformable hydrogel microparticles (microgels) with fibrin-binding ligands including a fibrin-specific whole antibody or a single-domain variable fragment. To improve the translational potential of these clotting materials, we explored the use of fibrin-binding peptides as cost-effective, robust, high-specificity alternatives to antibodies. Herein, we present the development and characterization of soft microgels decorated with the peptide AHRPYAAK that mimics fibrin knob 'B' and targets fibrin hole 'b'. These "Fibrin-Affine Microgels with Clotting Yield" (FAMCY) were found to significantly increase clot density
Identifiants
pubmed: 34095458
doi: 10.1002/adtp.202100010
pmc: PMC8171167
mid: NIHMS1689660
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : NHLBI NIH HHS
ID : R01 HL130918
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL146701
Pays : United States
Déclaration de conflit d'intérêts
Conflict of Interest Statement: Drs. Brown and Barker are Founders of SelSym Biotech, Inc. which is focused on developing injectable hemostatic materials.
Références
Am J Surg. 1980 Jul;140(1):144-50
pubmed: 7396078
Drug Discov Today. 2004 Jun 15;9(12):525-9
pubmed: 15183160
Chem Biol Drug Des. 2013 Jan;81(1):136-47
pubmed: 23253135
JAMA Surg. 2015 Apr;150(4):316-24
pubmed: 25693160
Nat Commun. 2017 Nov 2;8(1):1274
pubmed: 29097692
Chem Rev. 2017 Aug 9;117(15):10377-10402
pubmed: 28723101
Ann N Y Acad Sci. 1983 Jun 27;408:301-14
pubmed: 6575691
Adv Skin Wound Care. 2000 May-Jun;13(2 Suppl):6-11
pubmed: 11074996
Br J Pharmacol. 2009 May;157(2):220-33
pubmed: 19459844
Blood. 2007 Jan 1;109(1):130-8
pubmed: 16940416
Adv Biosyst. 2018 Oct;2(10):
pubmed: 33564714
Biomater Sci. 2019 Jan 29;7(2):669-682
pubmed: 30608063
J Clin Pharmacol. 2015 Mar;55 Suppl 3:S4-20
pubmed: 25707963
Biophys J. 2017 Feb 28;112(4):714-723
pubmed: 28256231
Blood Coagul Fibrinolysis. 2015 Jul;26(5):479-91
pubmed: 26126029
J Thromb Haemost. 2018 Nov;16(11):2159-2167
pubmed: 30182421
Soft Matter. 2015 Mar 14;11(10):2018-28
pubmed: 25648590
Biomaterials. 2013 Jan;34(2):526-41
pubmed: 23092864
Biomaterials. 2012 Jan;33(2):535-44
pubmed: 22018389
Blood. 2013 Mar 7;121(10):1712-9
pubmed: 23305734
J Biomed Mater Res B Appl Biomater. 2020 Aug;108(6):2599-2609
pubmed: 32100966
Chem Soc Rev. 2018 May 21;47(10):3574-3620
pubmed: 29479622
Biomaterials. 2015 May;49:27-36
pubmed: 25725552
Blood. 2011 Feb 3;117(5):1700-6
pubmed: 21106983
Blood. 2014 Mar 6;123(10):1596-603
pubmed: 24335500
J Am Coll Surg. 1998 May;186(5):528-33
pubmed: 9583692
Blood. 2005 Nov 1;106(9):2944-51
pubmed: 15998829
J Thromb Haemost. 2019 Feb;17(2):361-370
pubmed: 30582674
Crit Care. 2010;14(2):R52
pubmed: 20370902
Nat Mater. 2014 Dec;13(12):1108-1114
pubmed: 25194701
Bioconjug Chem. 2017 Jun 21;28(6):1649-1657
pubmed: 28398751
Langmuir. 2018 Jan 30;34(4):1457-1465
pubmed: 29257896